{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:16:46Z","timestamp":1793744206137,"version":"4.6.1"},"reference-count":25,"publisher":"BMJ","issue":"2","funder":[{"name":"National Occupational Research Agenda, NIOSH, CDC"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Occup Environ Med"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Mesothelioma is a rare, aggressive cancer caused by exposure to asbestos fibres. Mesothelioma patients who receive trimodal therapy (chemotherapy, surgical resection and radiation) survive longer than those who receive two or fewer therapy modalities. This study analyses the 2016\u20132019 Medicare claims data to estimate the burden of malignant mesothelioma and describe therapy patterns (when available) among continuously enrolled fee-for-service (FFS; Medicare parts A and B) beneficiaries.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We analysed claims and enrolment information from 42 529 117 FFS Medicare beneficiaries using three mesothelioma case definitions (broad, intermediate and narrow) with varying levels of diagnostic requirements. Results are presented as ranges of values for the three definitions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among FFS beneficiaries, 8213\u201319\u2009036 beneficiaries with mesothelioma were identified depending on the case definition. The annual prevalence per 100\u2009000 beneficiaries ranged from 8.8 in 2016 (narrow) to 31.3 in 2019 (broad) and annual incidence per 100\u2009000 beneficiaries ranged from 4.5 in 2019 (narrow) to 12.6 in 2017 (broad). Depending on the mesothelioma case definition, 41.8%\u201381.5% had available therapy claim information indicating that 7.6%\u201311.3% received chemotherapy alone, 1.3%\u20131.5% received radiation alone, and 14.3%\u201327.0% underwent surgery only, with 4.6%\u201310.5% receiving all three therapy modalities.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Mesothelioma was a prevalent disease among FFS Medicare beneficiaries during 2016\u20132019, and a limited proportion of beneficiaries received all three therapy modalities. Medicare data build on findings from cancer registry data to enhance our understanding of the mesothelioma burden and therapy patterns.<\/jats:p><\/jats:sec>","DOI":"10.1136\/oemed-2022-108706","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T18:25:48Z","timestamp":1673547948000},"page":"86-92","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Malignant mesothelioma among US Medicare beneficiaries: incidence, prevalence and therapy, 2016\u20132019"],"prefix":"10.1136","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4335-1700","authenticated-orcid":false,"given":"Laura","family":"Kurth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek M","family":"Mazurek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J","family":"Blackley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,1,12]]},"reference":[{"key":"2023121908300708000_80.2.86.1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13133127","article-title":"Mesothelioma","volume":"13","author":"Deraco","year":"2021","journal-title":"Cancers"},{"key":"2023121908300708000_80.2.86.2","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMra1912719","article-title":"Perspectives on the treatment of malignant pleural mesothelioma","volume":"385","author":"Janes","year":"2021","journal-title":"N Engl J Med"},{"key":"2023121908300708000_80.2.86.3","unstructured":"U.S. Cancer Statistics Working Group . U.S. cancer statistics data Vizualizations tool, 2022. U.S. department of health and human services, centers for disease control and prevention and National cancer Institute. Available: www.cdc.gov\/cancer\/dataviz"},{"key":"2023121908300708000_80.2.86.4","doi-asserted-by":"crossref","first-page":"214","DOI":"10.15585\/mmwr.mm6608a3","article-title":"Malignant Mesothelioma Mortality - United States, 1999-2015","volume":"66","author":"Mazurek","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2023121908300708000_80.2.86.5","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/ajim.22955","article-title":"North-South gradient of mesothelioma and asbestos consumption-production in the United States-Progresses since the 1st asbestos partial ban in 1973","volume":"62","author":"Sun","year":"2019","journal-title":"Am J Ind Med"},{"key":"2023121908300708000_80.2.86.6","unstructured":"Centers for Disease Control and Prevention . Incidence of malignant mesothelioma. USCS data brief, no. 27. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services, 2022."},{"key":"2023121908300708000_80.2.86.7","doi-asserted-by":"publisher","DOI":"10.1200\/JC0.2017.76.6394"},{"key":"2023121908300708000_80.2.86.8","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/ajim.23062","article-title":"Workshop summary: potential usefulness and feasibility of a US national mesothelioma registry","volume":"63","author":"Cummings","year":"2020","journal-title":"Am J Ind Med"},{"key":"2023121908300708000_80.2.86.9","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.athoracsur.2017.09.036","article-title":"National trends in the epidemiology of malignant pleural mesothelioma: a national cancer data base study","volume":"105","author":"Saddoughi","year":"2018","journal-title":"Ann Thorac Surg"},{"key":"2023121908300708000_80.2.86.10","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1002\/cncr.32355","article-title":"Unlocking the potential of population-based cancer registries","volume":"125","author":"Tucker","year":"2019","journal-title":"Cancer"},{"key":"2023121908300708000_80.2.86.11","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2147\/CLEP.S105396","article-title":"Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival","volume":"8","author":"Beebe-Dimmer","year":"2016","journal-title":"Clin Epidemiol"},{"key":"2023121908300708000_80.2.86.12","unstructured":"Chronic Conditions Data Warehouse . CCW technical guidance: getting started with CMS Medicare administrative research files version 2.8, 2022. Available: https:\/\/www.ccwdata.org\/web\/guest\/technical-guidance-documentation"},{"key":"2023121908300708000_80.2.86.13","unstructured":"Administration for Community Aging . 2020 profile of older Americans, 2021. Available: https:\/\/acl.gov\/sites\/default\/files\/aging%20and%20Disability%20In%20America\/2020Profileolderamericans.final_.pdf"},{"key":"2023121908300708000_80.2.86.14","unstructured":"Kaiser Family Foundation . Medicare beneficiaries as a percent of total population, 2022. Available: https:\/\/www.kff.org\/medicare\/state-indicator\/medicare-beneficiaries-as-of-total-pop\/?currentTimeframe=1&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D"},{"key":"2023121908300708000_80.2.86.15","unstructured":"Chronic conditions data Warehouse . Medicare enrollment charts. Available: https:\/\/www2.ccwdata.org\/web\/guest\/medicare-charts\/medicare-enrollment-charts"},{"key":"2023121908300708000_80.2.86.16","unstructured":"Research Data Assistance Center . Find, Request, and use CMS data, 2022. Available: https:\/\/www.resdac.org\/"},{"key":"2023121908300708000_80.2.86.17","unstructured":"Research Data Assistance Center . Master beneficiary summary file (MBSF) base, 2022. Available: https:\/\/www.resdac.org\/cms-data\/files\/mbsf-base"},{"key":"2023121908300708000_80.2.86.18","unstructured":"Research Data Assistance Center . Medicare fee-for-service data file search, 2022. Available: https:\/\/www.resdac.org\/cms-data?tid%5B%5D=4931&tid_1%5B%5D=1&=Find+Data+Files"},{"key":"2023121908300708000_80.2.86.19","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603293"},{"key":"2023121908300708000_80.2.86.20","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/ajim.23309","article-title":"Which ICD-9 codes were assigned for malignant mesothelioma in the mortality data in the United States before the ICD-10 was introduced?","volume":"65","author":"Tai","year":"2022","journal-title":"Am J Ind Med"},{"key":"2023121908300708000_80.2.86.21","unstructured":"Siedelman L . Diagnosis and procedure coding resources. Available: https:\/\/www.resdac.org\/articles\/diagnosis-and-procedure-coding-resources"},{"key":"2023121908300708000_80.2.86.22","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/ajim.22944","article-title":"Silicosis prevalence and incidence among Medicare beneficiaries","volume":"62","author":"Casey","year":"2019","journal-title":"Am J Ind Med"},{"key":"2023121908300708000_80.2.86.23","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01653-2015"},{"key":"2023121908300708000_80.2.86.24","unstructured":"Chronic Conditions Data Warehouse . Condition categories. Available: https:\/\/www2.ccwdata.org\/web\/guest\/condition-categories"},{"key":"2023121908300708000_80.2.86.25","unstructured":"National Cancer Institute . Procedure codes for SEER-Medicare analyses. Available: https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/considerations\/procedure_codes.html"}],"container-title":["Occupational and Environmental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/oemed-2022-108706","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T16:30:39Z","timestamp":1703003439000},"score":1,"resource":{"primary":{"URL":"https:\/\/oem.bmj.com\/lookup\/doi\/10.1136\/oemed-2022-108706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,12]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,1,18]]},"published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1136\/oemed-2022-108706"],"URL":"https:\/\/doi.org\/10.1136\/oemed-2022-108706","relation":{},"ISSN":["1351-0711","1470-7926"],"issn-type":[{"value":"1351-0711","type":"print"},{"value":"1470-7926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,12]]}}}